cid-103
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2021 (NCT04758767)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07017725 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2025 | CASI Pharmaceuticals, Inc. |
| NCT04758767 | Phase 1 | Mar 22, 2021 | CASI Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CASI Pharmaceuticals, Inc. | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1